AllDocs -> cancers

A214: Kidney and ureter cancer tissues For research use only (formalin fixed) Specifications: • No. of cases: 31 • Tissue type: Kidney and ureter cancer tissues ( kidney :28, ureter:3) • No. of spots: 2 spots from each cancer case (62 spots) 6 non-neoplastic spots (6 spots) • Total spots: 68 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: Page 2 A214: Kidney and ureter cancer tissues For research use only (formalin fixed) Summary of tissue spots No. Sex Age Key Word Grade TNM Stage 1 1,2 M 45 RCC.conventional type 1 T1aN0M0 (I) 2 3,4 ...

Chapter II.4 II.4-1 Cost of Kidney Cancer C HAPTER II.4. C OST OF K IDNEY C ANCER Clicking on the sections below will take you to the relevant text. II.4.A Background II.4.A.1 Description II.4.A.2 Concurrent Effects II.4.A.3 Causality II.4.A.4 Treatments and Services II.4.A.5 Prognosis II.4.B. Costs of Treatment and Services II.4.B.1 Methodology II.4.B.2 Results II.4.B.3 Limitations II.4.C. Conclusions Page 2 Chapter II.4 II.4-2 Cost of Kidney Cancer C HAPTER II.4. C OST OF K IDNEY C ANCER II.4.A Background This chapter contains a discussion of the methods used and ...

NCI Extramural Kidney Cancer Research Grants FY 2004 Grant Extracts for > 50% Kidney Cancer Relevance The following abstracts are for NCI-awarded grants for which 50% or greater share is for kidney cancer research. These grants comprise $15 million of the $22 million awarded in FY 2004 (September 1, 2004 – August 31, 2005) by the National Cancer Institute for kidney cancer related research. For a listing of all the grants refer to “NCI Kidney Cancer Budget” elsewhere on this website. Project Number Total Project Percent Relevant Kidney Cancer Institution Being Funded Funding to RCC Funding 5P50CA101942-2 $2,447,662 100.00 $2,447,662 BETH ISRAEL DEACONESS MEDICAL CENTER 5R01CA79830-5 322,000 100.00 322,000 BOSTON MEDICAL CENTER 5R21CA103486-2 ...

Prognostic Factors for Biologic Therapy in Kidney Cancer Beverly J. Drucker, MD, PhD Address Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 510, New York, NY 10021, USA. E-mail: druckerb@mskcc.org Current Urology Reports 2002, 3 :31 –36 Current Science Inc. ISSN 1527-2737 Copyright © 2002 by Current Science Inc. Introduction The incidence of renal cell carcinoma (RCC) is estimated to be approximately 26,000 new cases per year in the United States, with a death rate of 10,000 patients per year [1]. At the time of diagnosis, approximately 50% of patients have disease localized to the kidney , 20% of patients have locally advanced disease, and the remaining 30% of patients have distant metastases [1]. At present, surgical resection of all discernible disease is the only potentially curative therapy and is rarely an option for patients ...

Kidney Cancer Association Announces 'ACOR Challenge' KCA makes lead gift to online fundraiser to support email lists for cancer patients and survivors. (PRWEB) October 28, 2005 -- The Kidney Cancer Association (KCA), a suburban Chicago charity, today announced the "ACOR Thanksgiving Challenge," an online fundraiser for the benefit of the Association of Online Cancer Resources (ACOR). KCA chief executive officer Bill Bro said, "We're pleased to make the lead gift to the Challenge because we know how valuable the ACOR email lists are to families who are battling cancer ." ACOR is a 501 (c) (3) non-profit organization, incorporated in New York State. The heart of ACOR is a large collection of cancer -related Internet mailing lists , which delivered 1,847,431 e-mail messages last week to subscribers. In addition to supporting the mailing lists, ACOR develops and hosts state-of-the-art Internet-based ...

What You Need To Know About Kidney Cancer U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute ™ NIH Publication No. 03–1569 Revised April 2003 Printed September 2003 What You Need To Know About Index Page 2 This booklet is about kidney cancer . The Cancer Information Service can help you learn more about this disease. The staff can talk with you in English or Spanish. The number is 1–800–4– CANCER (1–800–422–6237). The number for deaf and hard of hearing callers with TTY equipment is 1–800–332–8615. The call is free. Este folleto es acerca del cáncer de riñon. Llame al Servicio de Información sobre el Cáncer para saber más sobre esta enfermedad. Este servicio ...

RISK FACTOR INFORMATION FOR SELECTED CANCER TYPES Source: Community Assessment Unit, Bureau of Environmental Health Assessment, Massachusetts Department of Public Health. July, 2001 Kidney cancer Kidney cancer involves a number of tumor types located in various areas of the kidney and renal system. Renal cell cancer ( which affects the main area of the kidney) accounts for over 90% of all malignant kidney tumors (ACS, 2001). The American Cancer Society estimates that there will be approximately 30,800 cases of kidney and upper urinary tract cancer, resulting in more than 12,100 deaths in 2001 (ACS, 2001). The incidence and mortality from kidney cancer is higher in urban areas, which may be due to increased access to screening and other factors such as smoking. Kidney cancer is twice as common in males as it is in females and the incidence most often occurs in the fifth and ...

3 3 New Vaccine Extends Prostate Cancer Survival A new vaccine is the first to extend survival among men with advanced prostate cancer . Men with advanced prostate cancer that is resis- tant to hormone-blocking therapy survive four and a half months longer, on average, with the new vaccine treatment, according to the results of a clinical trial led by UCSF urologic oncologist and Cancer Center member Eric Small. The phase III clinical trial included 127 men and was conducted at 19 sites across the country. Men received three infusions of either the vaccine or a placebo over a four-week period. Survival of men who received the vaccine aver- aged 25.9 months, compared with 21.4 months for men who received placebo. The only significant side effects reported were flu-like symptoms last- ing one or two days. Three years after the start of treatment, ...

kidney cancer News Release Penn State College of Medicine Tel: (717) 531-8606 Penn State Milton S. Hershey Medical Center Fax: (717) 531-6999 Strategic Services, A140 600 Centerview Drive P.O. Box 855 Hershey, PA 17033-0855 FOR IMMEDIATE RELEASE MEDIA INQUIRIES CONTACT: Monday, Sept. 26, 2005 Rebecca Haner (717) 531-1887 e-mail: rhaner@hmc.psu.edu KIDNEY TRANSPLANT PATIENTS FACE HIGHER SKIN CANCER RISK Penn State researchers to release largest study to date ...

Kidney Cancer Patient and Family Information and Support Program WHERE: Room 3052 in the Anschutz Cancer Pavilion 1635 N. Ursula St. Aurora, CO 80045 WHEN: 6:00p.m. to 7:30p.m. 2 nd Thursday of Every Month WHO: Patients, Family Members & Caregivers DATE: TOPIC: 1/13/2005 January Nutrition and Kidney Cancer [ Colleen Gill, MS, RD] 2/10/2005 February Palliative Care [Jean Kutner, MD and Harri Brackett, RN, BSN, OCN] 3/10/2005 March Radiation therapy and Kidney Cancer [ Brian Kavanagh, MD, MPH] 4/14/2005 April Clinical updates on Kidney Cancer [ Harry Drabkin, MD] 5/12/2005 May Clinical Trials and Kidney Cancer [ Bruno Medeiros, MD] 6/9/2005 June Pain Management [Rob Montgomery, ND, ...

National Cancer Institute SEER Program 56 KIDNEY AND RENAL PELVIS H istorically, incidence rates for kidney cancer have included cancers of the renal cells (in the main part of the kidney ) and the renal pelvis (the lower part of the kidney where urine collects before entering the ureter and continuing to the bladder), although there is evidence that these cancers have different characteristics. They are presented together here for continuity. About one of five kidney cancers occur in the renal pelvis. Internationally, the highest incidence rates occur in the United States, Canada, Northern Europe, Australia, and New Zealand. The lowest rates are in Thailand, China, and the Philippines. Rates in these countries are about one-third the rates in the high risk countries. During the years 1988 to 1992, in the ...

CANCER OF THE KIDNEY MEDICAL APPENDIX (including renal cell carcinoma, hypernephroma, nephroblastoma, Wilms’ tumour, squamous cell carcinoma, transitional cell carcinoma, sarcoma) DEFINITION 1. Cancer is a term which embraces a large number of different diseases, the common feature of which is a malignant tumour. This is a growth (neoplasm) which is not circumscribed but which infiltrates the surrounding tissues and metastasises (spreads to other sites in the body), thereby producing secondary deposits. Any tissue in the body may be affected. 2. Cancers are classified according to the tissue of origin. Carcinoma arises from epithelial tissue and sarcoma from connective tissue. The suffix blastoma implies a tumour of embryonic origin. 3. There are three main types of cancer of the kidney : 3.1. Nephroblastoma (Wilms’ tumour) is a rare tumour, occurring in ...

Age Sex Diagnosis Size(cm) Capsule Vein Other N M 1 52 F RCC, granular cell types 12 + - - NX M0 2 60 F RCC, clear cell type 6 + + - N0 M1 3 42 M RCC, clear cell type 9 + + - NX M0 4 59 M RCC, clear cell type 7.5 + - - NX M0 5 67 F RCC, clear cell and granular cell type 8 + - - NX M0 6 65 M RCC, granular and clear cell type 11 + - - NX M0 7 59 M RCC, clear cell and granular cell type 7 + + - NX M0 8 56 M RCC, clear and pseudosarcomatous type 7 + - - NX M1* 9 42 F RCC, clear cell type 10 - + - NX ...

© 20 05 B JU I N TER N A TI O N A L | 9 5, 11 71– 11 8 0 | doi:10.1111/j.1464-410X.2005.05535.x 11 71 Blackwell Science, LtdOxford, UKBJUBJU International1464-410XBJU InternationalJune 2005 959 Mini-rev Article NEW DRUGS AND MOLECULAR TARGETED THERAPY MANCUSO and STERNBERG What’s new in the treatment of metastatic kidney cancer? ANDREA MANCUSO and CORA N. STERNBERG Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy Accepted for publication 7 March 2005 KEYWORDS renal cancer, new regimens, anti-angiogenic therapy, targeted therapies INTRODUCTION RCC is the sixth leading cause of cancer death in the USA, and the incidence of RCC in Europe is increasing, with ª20 000 new cases each year and an annual death rate from metastatic disease of ª8000 per year. Surgery is the ...

In 2002, there were 2,031 cases of invasive cancer of the kidney and renal pelvis diagnosed among residents of Pennsylvania, the highest annual number since statewide reporting began in 1985. Males had an average annual (1998-2002) age-adjusted incidence rate approximately twice that of females (18.3 and 9.4 per 100,000, respectively). For the years 1993 through 2002, annual numbers of cases and age-adjusted incidence rates for white and black males and white females have been on the increase. Among black females, the annual incidence rates for this ten-year period increased though 1998 and then decreased through 2001. There are few understood causes of kidney cancer; however, cigarette smoking is an important risk factor. Approximately a quarter of all cases are caused by this behavior. As with age-adjusted rates, age-specific incidence rates were much higher among males for almost all age groups. Over 61 percent of the cases for ...

KIDNEY CANCER UK Fifth Annual Conference Saturday 4 June 2005 Royal Marsden Education and Conference Centre Stewart’s Grove, Chelsea, London SW3 6JJ PROGRESS IN KIDNEY CANCER RESEARCH, TREATMENT AND PATIENT/CARER SUPPORT Programme 09.30 onwards Registration, refreshments and information 10.15 Welcome and introduction Keith Taylor, President of Kidney Cancer UK 10.30 ‘The evolution of technologies for the surgical treatment of kidney cancer’ Mr. Chris Anderson, Consultant Urologist, St. George’s Hospital, and Cromwell Hospital Specialist Urology Centre 11.20 Refreshments 11.40 ‘Oncology and kidney cancer: past achievements, future prospects’ Professor R. T. D. Oliver, Professor of Medical Oncology, St. Bartholomew’s Hospital 12.30 Buffet lunch 13.30 ‘Working in harmony: CAM ...

KIDNEY CANCER UK Fifth Annual Conference Saturday 4 June 2005 Royal Marsden Education and Conference Centre Stewart’s Grove, Chelsea, London SW3 6JJ PROGRESS IN KIDNEY CANCER RESEARCH, TREATMENT AND PATIENT/CARER SUPPORT REGISTRATION FORM To Kidney Cancer UK: Please register the person(s) named below for the Fifth Annual KCUK Conference on 4 June 2005. I enclose a cheque (made payable to KCUK) for the total amount due. Title/Name (BLOCK CAPITALS): Signed: Date: Organisation (if applicable): Address: Telephone: E-mail: Title/Name Fee category: A, B, C or D? Lunch Required? Amount Due 1 YES/NO £ 2 YES/NO £ 3 YES/NO £ 4 YES/NO £ CHEQUE ENCLOSED FOR TOTAL AMOUNT: £ Fee categories are as follows: ...

research for a cure laboratory without walls National Foundation for Cancer Research Cancer FAQs about kidney cancer Frequently Asked Questions about common cancers. Page 2 Cancer FAQs What are the different types of kidney cancer? By far the most common type of kidney cancer is renal cell carcinoma , accounting for about 85 percent of cases. There are five main forms of renal cell cancers, each differentiated by the way the cancerous cells appear under a microscope. They include: clear cell (about 70–80 percent of renal cell cancers), papillary (about 10–15 percent of renal cell cancers), chromophobe (about 5 percent), collecting duct (very rare), and “unclassified,” which means the appearance of the cancer cells doesn’t fit into any of the other four main categories (about 5 percent). The type of renal cell ...

A214: Kidney and ureter cancer tissues For research use only (formalin fixed) Specifications: • No. of cases: 31 • Tissue type: Kidney and ureter cancer tissues ( kidney: 28, ureter:3) • No. of spots: 2 spots from each cancer case (62 spots) 6 non-neoplastic spots (6 spots) • Total spots: 68 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: Page 2 A214: Kidney and ureter cancer tissues For research use only (formalin fixed) Summary of tissue spots No. Sex Age Key Word Grade TNM Stage 1 1,2 M 45 RCC.conventional type 1 T1aN0M0 (I) 2 3,4 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN KIDNEY CANCER TISSUE MICROARRAY Catalog Number: TMA-019 Each core from each tissue represents one specimen selected and pathologically confirmed. Normal matched or unmatched kidney tissue is provided for comparison to the cancer tissue. Cases : 40 Cores : 80 Diameter : 1.5 mm Thickness: 5 µm Standard IHC: Cytokeratin confirmed Layout : 8 x 10 1 2 3 4 5 6 7 8 9 10 A 1 2 3 4 5 6 7 8 9 10 B 11 12 13 14 15 16 17 18 19 20 C 21 22 23 24 25 26 27 28 29 30 ...

kidney cancer 1581 Interleukin-2/ CCI-779 Trials Dr. David Minor California Pacific Medical Center March 19, 2005 IL-2 Biological Effects Proliferation of Lymphocytes in test tube and in the patient Activation of lymphocytes Natural Killer Cells Lymphokine-Activated Killer Cells Trafficing of Lymphocytes Cells move into tissues Production of Cytokines gamma-interferon tumor necrosis factor interleukin-5: growth factor for eosinophils Post-Surgical High-Dose IL-2 Therapy 44 patients locally advanced randomized to observation or two 5-day cycles of high-dose interleukin-2 therapy 25 patients had resected metastatic disease also included Two-year disease-free survival 48% ...

Trends in Cancer Incidence in Queensland Cancer of Kidney And Other Renal Tract Rate per 100,000 population Incidence of Cancer of Kidney And Other Renal Tract, by Sex, Queensland, 1982 to 2002 Male Female 0 3 6 9 12 15 18 21 Year 1982 1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 Note: Rates are age standardised to the Australian population as at 30 June 2001. Data are reported by year of diagnosis. Cancer of Kidney And Other Renal Tract is defined by the ICD-0-2 codes of C64 to C66 and C68 Source: Queensland Cancer Registry, Queensland Health and Queensland Cancer Fund. Generated by Epidemiology Services Unit, Queensland Health For more information: Health Status Indicators for Queensland Queensland Health Cancer ...

Trends in Cancer Mortality in Queensland Cancer of Kidney And Other Renal Tract Rate per 100,000 population Mortality of Cancer of Kidney And Other Renal Tract, by Sex, Queensland, 1982 to 2002 Male Female 0 3 6 9 12 15 Year 1982 1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 Note: Rates are age standardised to the Australian population as at 30 June 2001. Data are reported by year of diagnosis. Cancer of Kidney And Other Renal Tract is defined by the ICD-0-2 codes of C64 to C66 and C68 Source: Queensland Cancer Registry, Queensland Health and Queensland Cancer Fund. Generated by Epidemiology Services Unit, Queensland Health For more information: Health Status Indicators for Queensland Queensland Health Cancer Publications ...

Cancer Incidence by Remoteness Category in Queensland Cancer of Kidney And Other Renal Tract 0 3 6 9 12 15 18 21 24 0 3 6 9 12 15 18 21 24 Male Female Rate per 100,000 population Rate per 100,000 population Avg No. Avg No. per Year per Year Incidence of Cancer of Kidney And Other Renal Tract, by ARIA+ Category and Sex, Queensland, Five Year Average, 1998 to 2002 18.0 144 10.4 98 Major City ARIAplus Category 16.7 79 10.6 54 Inner Regional 15.6 43 7.8 22 Outer Regional 12.8 3 10.0 2 Remote 11.6 2 4.9 1 Very remote Note: Rates are age standardised ...

Age-specific Cancer Incidence in Queensland Cancer of Kidney And Other Renal Tract Rate per 100,000 population Incidence of Cancer of Kidney And Other Renal Tract, by Age Group and Sex, Queensland, Five Year Average, 1998 to 2002 Male Female 0 10 20 30 40 50 60 70 80 90 100 Age group (years) 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85+ Note: Age-specific rates are averaged over the five years, and based on age at time of diagnosis. Only the first year of each 5-year age group is displayed on the x-axis. Cancer of Kidney And Other Renal Tract is defined by the ICD-0-2 codes of C64 to C66 and C68 Source: Queensland Cancer Registry, Queensland Health and Queensland Cancer Fund. Generated by ...

Cancer Mortality by Remoteness Category in Queensland Cancer of Kidney And Other Renal Tract 0 3 6 9 12 15 0 3 6 9 12 15 Male Female Rate per 100,000 population Rate per 100,000 population Avg No. Avg No. per Year per Year Mortality of Cancer of Kidney And Other Renal Tract, by ARIA+ Category and Sex, Queensland, Five Year Average, 1998 to 2002 6.2 47 3.6 35 Major City ARIAplus Category 5.4 24 4.1 22 Inner Regional 7.4 18 3.8 10 Outer Regional 3.8 1 4.7 1 Remote 2.8 1 3.9 1 Very remote Note: Rates are age standardised to the Australian population as at 30 June 2001. Numbers ...

Cancer Mortality by Geographical Reporting Area in Queensland Cancer of Kidney And Other Renal Tract 0 3 6 9 12 15 0 3 6 9 12 15 Male Female Rate per 100,000 population Rate per 100,000 population Avg No. Avg No. per Year per Year Mortality of Cancer of Kidney And Other Renal Tract, by Geographical Reporting Area and Sex, Queensland, Five Year Average, 1998 to 2002 5.8 4 3.9 4 Bayside Geographical Area 5.4 11 3.9 11 Brisbane North 7.2 12 2.9 6 Brisbane South 7.0 8 4.4 6 Darling Downs/Sth West 5.5 5 3.4 3 Far North 7.1 5 4.3 4 Fitzroy/Central ...